Company Overview and News

to your dashboard

Headline News

Alnylam Starts Rolling NDA Submission for RNAi Candidate

7h zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has initiated submission of a rolling New Drug Application (NDA) to the FDA for lead candidate patisiran. The candidate is an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis.  The rolling submission allows completed portions of an NDA to be reviewed by the FDA on an ongoing basis. (49-0)

Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

2017-11-16 zacks
Shares of Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) have soared 236.4% year to date compared with the industry’s gain of 0.2%. Here we analyze the factors that led to the rally. (59-0)

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

2017-11-16 reuters
* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis (17-0)

7 Vanguard ETFs to Build a Total Portfolio

2017-11-14 investorplace
When you’re putting together a portfolio — whether you’re starting one tomorrow, or you’re looking to tinker with what you’ve got — there are a few basics that most investors aim for: U.S. stocks. International holdings. Fixed income. (57-0)

Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

2017-11-14 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has granted an accelerated assessment for patisiran. (72-0)

Biotech ETFs: What Lies Ahead?

2017-11-13 zacks
So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date. This is in sharp contrast to last year’s performance when the Index was down 19.1% with several factors including the drug pricing controversy weighing on the sector. (177-0)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-8)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q4 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences Fourth Quarter Investor Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (98-1)

Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

2017-11-08 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) incurred a loss of $1.34 per share in the third quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.23. The figure was also wider than the year-ago loss of $1.21. (41-0)

Sarepta Therapeutics Will Continue To Ride High On EXONDYS 51's Success In 2017

2017-11-08 seekingalpha
EXONDYS 51 is seeing rising demand, thanks to increasing adoption of genetic testing and higher patient compliance rates. (210-1)

Alnylam Pharmaceuticals (ALNY) Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss The Third Quarter 2017 Financial Results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request. (38-0)

Featured Company News - Alnylam Shares Positive Preliminary Results from Ongoing Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

2017-11-07 accesswire
LONDON, UK / ACCESSWIRE / November 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) ("Alnylam"), following which we have published a free report that can be viewed by signing up at The Company announced on November 03, 2017, positive preliminary data from its ongoing Phase-1/2 study of Lumasiran. (39-0)

Alnylam Pharmaceuticals (ALNY) a Buy on Healthy Quant Score

2017-11-07 investorplace
Currently, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month. (17-0)

What's in Store for Ligand (LGND) This Earnings Season?

2017-11-06 zacks
Ligand Pharmaceuticals Inc. (LGND - Free Report) is scheduled to report third-quarter 2017 results on Nov 9, after the market closes. Ligand’s earnings history has been a mixed bag with the company having surpassed expectations in two of the last four quarters and missed in the other two. It also delivered an average positive surprise of 6.19%. (70-0)

CUSIP: 02043Q907